Doehn C, Jocham D
Department of Urology, Medical University of Luebeck, Ratzeburger Allee 160, 23538 Luebeck, Germany.
Curr Opin Mol Ther. 2000 Feb;2(1):106-11.
Tumor-associated antigens have considerable promise not only as diagnostic or prognostic markers but also as targets for active or passive immunotherapy. The epithelial mucin MUC1 is a transmembrane molecule which is expressed by most glandular epithelial cells. Transgene has developed VV-MUC1-IL-2 (TG-1031), an antigen-specific therapy, involving the tumor antigen MUC1 and the cytokine IL-2 combined with a vaccinia virus vector. Vaccinia virus vectors have been shown to stimulate a strong immune response to encoded antigens in vivo. This therapy has potential for the treatment of breast cancer, prostate cancer and other adenocarcinomas and is currently under investigation in phase I and II trials.
肿瘤相关抗原不仅作为诊断或预后标志物具有巨大潜力，而且作为主动或被动免疫治疗的靶点也具有巨大潜力。上皮粘蛋白MUC1是一种跨膜分子，大多数腺上皮细胞都可表达。转基因公司已研发出VV-MUC1-IL-2（TG-1031），这是一种抗原特异性疗法，涉及肿瘤抗原MUC1和细胞因子IL-2与痘苗病毒载体相结合。痘苗病毒载体已被证明能在体内刺激对编码抗原产生强烈的免疫反应。这种疗法具有治疗乳腺癌、前列腺癌和其他腺癌的潜力，目前正处于I期和II期试验研究中。
